These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 2957052)

  • 21. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
    Yoshida M; Murai H; Miura S
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of marked effectiveness using medroxyprogesterone acetate (MPA) in lung metastases of cancer of the uterine body].
    Takeda M; Kubo K; Fukushima M; Hirayama J; Sekiguchi M
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2113-7. PubMed ID: 2145808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of carcinoma of the breast with high dose oral medroxyprogesterone acetate: does increased bioavailability improve the therapeutic ratio?
    Roberts JT; Bates T; Bozzino JM; Brock JE; Clarke DG; Durrant KR; Evans RG; Tobias JS
    Clin Oncol (R Coll Radiol); 1990 Nov; 2(6):324-7. PubMed ID: 2149061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages.
    Papaleo C; Carella C; Zito GA; Figlia A; Capuano F; Amato G
    Chemioterapia; 1984 Aug; 3(4):220-2. PubMed ID: 6099752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Embryotoxicity of a single dose of medroxyprogesterone acetate (MPA) and maternal serum MPA concentrations in cynomolgus monkey (Macaca fascicularis).
    Prahalada S; Carroad E; Cukierski M; Hendrickx AG
    Teratology; 1985 Dec; 32(3):421-32. PubMed ID: 2934853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.
    Tveter KJ; Hagen S; Holme I; Klepp O; Kloster SE; Muri O; Poulsen C; Sander S; Sivertsen S; Urnes T
    Scand J Urol Nephrol; 1990; 24(4):243-7. PubMed ID: 2148830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.
    Etienne MC; Milano G; René N; Benedetti MS; Efthymiopoulos C; Vo Van ML; Hurteloup P; Montcuquet P; Frenay M; Namer M
    J Pharm Sci; 1991 Dec; 80(12):1130-2. PubMed ID: 1839998
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate].
    Etienne MC; Milano G; Namer M
    Bull Cancer; 1993 May; 80(5):431-8. PubMed ID: 8173196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MPA at high doses in advanced breast cancer: a statistical evaluation.
    Pannuti F; Camaggi CM; Strocchi E; Martoni A
    Chemioterapia; 1986 Jun; 5(3):159-63. PubMed ID: 2941172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.
    Blossey HC; Bartsch HH; Kanne D; Koebberling J; Nagel GA
    Cancer Chemother Pharmacol; 1982; 8(1):77-81. PubMed ID: 6212156
    [No Abstract]   [Full Text] [Related]  

  • 33. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma concentrations of medroxyprogesterone acetate and megesterol acetate during long-term follow-up in patients treated for metastatic breast cancer.
    Miller AA; Becher R; Schmidt CG
    J Cancer Res Clin Oncol; 1988; 114(2):186-90. PubMed ID: 2965155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolism of medroxyprogesterone acetate and hepatic drug metabolism activity.
    Rautio A; Saarni HU; Arranto AJ; Stengård JH; Kärki NT; Sotaniemi EA
    Res Commun Chem Pathol Pharmacol; 1985 Feb; 47(2):305-8. PubMed ID: 3158039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Wander HE; Nagel GA; Blossey HC
    Onkologie; 1982 Aug; 5 Suppl():28-33. PubMed ID: 6215600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
    Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
    J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
    Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract]   [Full Text] [Related]  

  • 39. Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.
    Yamashita J; Hideshima T; Shirakusa T; Ogawa M
    Cancer; 1996 Dec; 78(11):2346-52. PubMed ID: 8941005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloprotective effect of high dose medroxyprogesterone acetate (MPA).
    Wils JA
    Chemioterapia; 1988 Feb; 7(1):60-2. PubMed ID: 2967738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.